World Health Organization site
Skip Navigation Links

Main
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 17 October 2012
Main ID:  NCT00429897
Date of registration: 31/01/2007
Primary sponsor: University of Cambridge
Public title: Double Blind Crossover Comparison of Diuretics in the Young
Scientific title: Double Blind Crossover Comparison od Diuretics in Young Patients With Low Renin Hypertension
Date of first enrolment: August 2006
Target sample size: 30
Recruitment status: Recruiting
URL:  http://clinicaltrials.gov/show/NCT00429897
Study type:  Interventional
Study design:  Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment  
Countries of recruitment
United Kingdom
Contacts
Name:   Morris J Brown, Proffessor
Address: 
Telephone: 01223 336743
Email: mjb14@medschl.cam.uk
Affiliation: 
Name:   Morris J Brown, Professor
Address: 
Telephone: 01223 336743
Email: mjb14@medschl.cam.ac.uk
Affiliation: 
Name:   Morris J Brown, Proffessor
Address: 
Telephone:
Email:
Affiliation:  Cambridge University
Key inclusion & exclusion criteria

Inclusion Criteria:

- Aged 18-45

- male or female

- Hypertensive - 3 clinic SBP >=140mmHg; or 3 clinic DBP >=90mmHg; or ABPM or home BP
>=130(SBP) or 85(DBP)

- 24hr Na+<160mmol/l

- EITHER {Plasma renin<=10mU/L (measured untreated, or whilst receiving only
CCB+/-diuretic} + {Plasma renin <=40mU/L (measured on an ACEi or ARB, which
approximately double s the plasma renin)} OR Plasma renin <5mU/L (measured untreated,
or receiving any antihypertensive drug other than a beta-blocker

Exclusion Criteria:

- Documented history of gout

- Abnormal renal function (both elevated serum creatinine and reduced creatinine
clearance

- SBP > 170mmHg or Diastolic >110mmHg despite treatment with permitted background
treatment



Age minimum: 18 Years
Age maximum: 45 Years
Gender: Both
Health Condition(s) or Problem(s) studied
Low-Renin Hypertension
Intervention(s)
Drug: Amiloride 20-40mg
Drug: Bendroflumethiazide 1.25-2.5mg/ Amiloride 10-20mg combined
Drug: Bendroflumethiazide 2.5mg - 5mg
Drug: Frusemide 20-40mg
Drug: Spironolactone 50-100mg
Primary Outcome(s)
Difference in plasma renin for subjects' best drug and second best drug.
Difference in systolic blood pressure for subjects' best drug and second best drug.
Secondary Outcome(s)
Predictions of best drug
Secondary ID(s)
1.0
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
British Heart Foundation
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.1 - Version history